

Index

Note: page numbers in *italics* refer to figures or tables

- Acetyl choline (ACh) 401–4
Acinetobacter baumannii 254
Actin 35
Activator protein (AP)-1 371, 372–3, 375–6, 397, 371
Acute respiratory distress syndrome (ARDS) 157, 158–60
ADAM 17 (TACE) 264, 360
ADAM 33 359
Adenoviruses 226, 421
Adherens junctions (AJs) 27, 28, 30, 34–5
Adhesins 254, 255, 256
Adhesion structures
 cell–cell 27–37, 28, 30
 allergens 303–4, 310–6, 320–1
 asthma 353–4
 cell–substratum 28, 30, 38–45, 341
 epithelial shedding–repair 77, 79, 82
 mechanisms of damage in COPD 66
 microbial recognition 175
Aerosol drug delivery 412–17, 422–3
Air–liquid interface 149–52
Airway surface liquid (ASL) 91, 92–3, 101–5
 activity of AMPs in 192–3
 aerosol particles 415, 416
 reactive oxygen species 195–6
 see also Mucus
Allergen–epithelium interaction 301–21
 asthma 58–9, 280–1, 301, 305, 318, 320–1, 332, 351–2
 epithelial repair 82, 314–16
 pollutants 63, 280–1
 viral infections 241
Alveolar epithelial cells 29, 32–3, 42–3, 62, 64–5, 377–9
 see also Alveolar type I cells; Alveolar type II cells
Alveolar macrophages 153, 154, 416–17
Alveolar physiology
 role of fluid 89–92
 surface tension 149–52
Alveolar type I cells 2, 11, 15, 106–7, 417–19
Alveolar type II cells 2, 11–12, 15
 cell–cell adhesion 32–3
 drug absorption 417–19
 fluid transport across 106, 107
 fluid volume regulation 90
 microbial recognition 176
 pollutants 287
 proliferation potential 12
 surfactant 149, 154–5, 156, 157
 TLR expression 172, 173
Anoikis 41
Anti-inflammatory epithelial cells 342–4
Anti-inflammatory therapy
 epithelial repair 83–4
 β_2 -adrenoceptor agonists 60, 84, 391–401, 413–14
 glucocorticoids 60, 63, 84, 212, 367–82
 with β_2 -agonists 391, 392, 393–401
 muscarinic receptor antagonists 391–2, 401–4, 414
 see also Drug delivery systems
Antibodies, aerosol delivery 423

- Anticholinergics 391–2, 401–4, 414
- Antigen presentation 209–12, 302–3, 325
see also Dendritic cells (DC)
- Antimicrobial molecules 187–97, 229–30, 257
 AMPs, *see* Antimicrobial peptides and proteins (AMPs)
 reactive nitrogen species 195, 196, 230, 263, 339–40
 reactive oxygen species 195–6
- Antimicrobial peptides and proteins (AMPs) 175, 187–95, 262, 337
see also Defensins; Surfactant proteins (SP), Immune system
- Antioxidant defences 288, 354
- Antioxidant production 338, 343
- Apoptosis
 allergen–epithelium interaction 316–17
 asthma 59, 60, 61, 79
 emphysema 64–5
 obliterative bronchiolitis 67
 role of integrins 41
 virus-infected 240
 in vitro/in vivo systems 79
- Aquaporins (AQPs) 377–9
- Arachidonic acid 335–6, 376, 380
- Aspergillus* spp 306, 306–8, 318
- Asthma 351–2
 allergens 58–9, 280–1, 301, 305, 318, 320–1, 332, 351–2
 AMPs 193
 cigarette smoke 290
 epithelial shedding 57–8, 61, 67, 135
 repair 76, 77, 79–81, 83, 84–6
 goblet cell hyperplasia 60, 137, 140, 360
 goblet cell metaplasia 360
 immunoregulation–epithelium relation 207, 208, 212, 213
 inflammation 332, 334–5, 336, 337, 340, 341
 microbial recognition by epithelium 172, 176
 mucociliary clearance 136–7
 ciliary dysfunction 119–20, 135–6, 140
 MUC genes and products 134, 139, 360
 mucus hypersecretion 129, 135–6, 137–40, 360
 pathophysiology 57–61, 67
 airway remodelling 351–61, 376–7, 393
 allergen exposure 58–9, 61, 280–1
 anti-inflammatory therapy 60, 84, 361, 393
 cell type distribution 60–1
 epithelial repair 84–6, 353–5
 glucocorticosteroids 60, 61, 84
 inflammatory cells 58–60, 85, 351–3, 357, 359, 360, 361
 pollutants 61, 242, 278, 280–2, 285, 290
 therapy, *see* Anti-inflammatory therapy
 viral exacerbation 211, 225, 226–7, 231–7, 242, 281–2, 332, 377
- ATP 92, 94, 95, 103, 105, 377–9
- AU-rich elements (AREs) 374
- Avian influenza 239
- Axonemes 3, 111–12, 113–16
see also Dynein arms
- B-cells 205, 206, 212–13
- B7 ligands 210–2
- Bacteria and bacterial infections 253–65
 allergens 308
 antimicrobial molecules 187–8, 189–91, 194, 196, 257, 262–3
 asthma 140, 172
 ciliary dysfunction 118–19, 120
 COPD 64, 66, 140, 227, 241, 254
 epithelial cell responses 261–5
 lung damage 264–5
 pneumonia 253–4, 256, 261–2, 264
 recognition by epithelium 170–2, 175–7, 256–61
 surfactant proteins 153–4, 190
 viral co-infection 241, 242
 virulence factors 254–6
- Basal cells 2, 3, 4
 M cells 205
 proliferation 4–5
 shedding-repair 75, 77, 77–8, 80
 stem cell potential 4
- Basal lamina 352, 356–7
- Bestrophins 95
- β_2 -adrenoceptor agonists 60, 84, 391–401, 413–14
- Biofilms 254, 255–6
- Bone marrow-derived cells 13–14
- BP230 44–5
- Bronchial-associated lymphoid tissue (BALT) 205–6
- Bronchial epithelium 2
 cell types 2–8, 93
 cell–cell adhesion 29
 pollutants 278, 279, 283–4, 285, 289
 production of lipid mediators 336
 TLR expression 172, 173

- Bronchioalveolar stem cells (BASCs) 10
 Bronchioles 2, 9–10, 15, 90, 93
 Bronchiolitis 67, 226, 236, 237
 Bronchitis 119, 134, 135, 136, 422
 Brush cells 2, 8, 29
 Bullous pemphigoid antigen (BP)-180 44, 45
- Cadherins 30, 35, 35(n3), 36, 204
 Calcium-activated chloride channels (CaCCs)
 90, 92, 93, 94–5, 98, 100
 ASL volume regulation 103, 105
 glucocorticoids 380
 Calcium ion dependent signalling 263
 Calcium-mediated CBF 116, 117
 Calcium responses, allergens 318–20
 cAMP-dependent CBF regulation 115–16, 117
 cAMP-responsive element-binding protein
 (CREB) 263
 CAR-like membrane protein (CLMP) 34
 Cardiovascular disease 286–7, 290
 Cartilaginous proximal airway region 2–9, 14,
 29
see also Bronchial epithelium; Submucosal
 glands (SMGs); Tracheal epithelium
 Caspase activation 240, 261, 354–5
 Catenins 35, 37
 Cathelicidins 188, 189, 194, 262, 337
 Cationic epithelial proteinase inhibitors 188,
 190
see also Elafin; Secretory leukocyte protease
 inhibitor (SLPI)
 Caveolin 418
 CC Chemokines 333–5
 allergens 318, 334–5
 bacterium–epithelium interaction 262, 264
 CCL5, *see* RANTES (CCL5)
 dendritic cells 204
 glucocorticoids 368
 pollutants 285
 T-cell recruitment into airways 209
 viral infections 229, 231–2, 237, 238, 239,
 240
 Cell types 1–15, 57, 93, 137
 Cell–cell adhesion, *see* Adhesion structures,
 cell–cell
 Cell–substratum adhesion 28, 30, 38–45, 341
 cGMP 117
 Channel-activating proteases (CAP) 104–5
 Chemokines 332–5
 allergens 317–18, 319, 320, 334–5
 antimicrobial 190, 194
 asthma pathophysiology 58, 59, 61, 64, 282,
 318, 355
 bacterium–epithelium interaction 258, 259,
 260, 261–3, 264
 β_2 -adrenoceptor agonists 392–3, 396
 CF pathophysiology 67
 COPD pathophysiology 62, 63, 64, 66
 dendritic cells 203, 204–5
 glucocorticoids 368, 371, 373, 374
 microbial recognition 174–5, 258
 pollutants 278, 279, 282, 284, 285, 289
 T-cell recruitment 208, 209
 TSLP action on 207
 viral infections 229, 231–6, 237–8, 239–40,
 241, 242, 282, 396
 Chloride channels 91
 alveolar epithelium 106, 107
 ASL volume regulation 102–4, 105
 Calcium-activated 90, 92, 93, 94–5, 98, 100,
 103, 380
 CFTR pathway 90, 92, 93, 100, 196
 glucocorticoids 377, 378, 380
 Ussing chamber studies 98, 99
 in vivo transepithelial PDs 100
 Chronic bronchitis 119, 134, 135,
 136, 422
 Chronic obstructive pulmonary disease (COPD)
 AMPs 193
 anticholinergics 401–2
 bacteria and infections 64, 66, 140, 227,
 241, 254
 combination therapies 395, 397
 epithelial shedding 67, 76
 goblet cell hyperplasia 137
 mechanisms of epithelial damage 62–6, 67
 cigarette smoke 62–3, 64–6, 67, 288,
 343, 402
 emphysema 64–5, 79
 epithelial repair defects 83, 85
 mucociliary clearance 136, 140
 mucus hypersecretion 129, 134–5, 137–40
 pollutants 62–6, 67, 285, 288, 343
 viral exacerbation 225, 226, 227, 231,
 234, 241
 Cigarette smoke 287–90
 airway mucus secretion 132
 COPD 62–3, 64–6, 67, 136, 288,
 343, 402
 reactive oxygen/nitrogen species 288,
 338, 343
 viral infections 241

- Cilia
 dysfunction 118–20, 135–6, 140
 function 3–4, 111, 114–18
 pollutants 277
 RSV infection 237
 structure 3, 111–14
- Ciliary beat frequency (CBF) 113, 115–18, 119–20, 392
- Ciliary dyskinesia 118
- Ciliated cells 2, 3–4, 5, 9
 cell–cell adhesion 29
 CFTR expression 94
 ion and solute transport 90, 91, 93, 101–4
 mechanisms of damage in COPD 66
 repair following shedding 75–82, 77–8
 RSV infection 237, 238
see also Cilia
- Clara cell secretory protein (CC10) 9–10, 375
- Clara cells 2, 6, 9–10, 15
 cell–cell adhesion 29
 goblet cell hyperplasia 137, 141
 mechanisms of epithelial damage 61, 67, 137
- Claudins 29, 30, 32–3, 34, 303, 311, 313
- Collectins 148–9
 biophysical function 152
 immune function 153–4, 159–60, 190, 229
 synthesis 155
- Community-acquired pneumonia 226, 253, 254
- Complement component C3 190
- Corticosteroids, *see* Glucocorticoids
- Cough 136
- Coxsackie and adenovirus receptor (CAR) 34
- CX3C chemokines 203, 237–8, 333, 335
- CXC chemokines 333, 334
 cigarette smoke 62
 dendritic cells 204–5
 pollutants 289
 T-cell recruitment into airways 209
 viral infections 231–6, 237, 238
see also Interleukin-8 (IL-8; CXCL8 (IL-8))
- Cyclooxygenase (COX) pathway 289, 335–6, 376
- Cystic fibrosis (CF)
 AMPs 193
 bacterial colonization 254, 256
 biofilm production 256
 ciliary dysfunction 120
 gene therapy 421
 goblet cell hyperplasia 137, 140
 ion and solute transport 99, 100, 101, 102–4, 105, 193, 196
 mechanisms of epithelial damage 66–7
 mucus hypersecretion 137–40
 protease inhibitors 342, 420
 surfactant 422
 TLR polymorphisms 172
 viral infections 230
- Cystic fibrosis transmembrane regulator (CFTR) 66–7, 93–4
 alveolar epithelium 106, 107
 ASL volume regulation 103, 104, 105
 bacterial infections 254
 chloride ion conductance 90, 92, 93, 100, 196
 ENaC regulation 97
 gene transfer 421
 reactive oxygen species 195, 196
 serous cells of submucosal glands 8–9, 94
 Ussing chamber studies 98
 in vivo transepithelial PDs 100
- Cytochrome p-450 monooxygenase enzymes 336
- Cytokeratins 36
- Cytokines and growth factors 330, 355, 356–7, 360, 361, 377
 action on T-cells 206, 207, 208–9, 210–1, 331
 airway mucus secretion 132
 allergens 317–20
 AMPs 191, 192, 262
 asthma pathophysiology 58–9, 61, 64, 332
 airway remodelling 355, 356–7, 360, 361
 allergen exposure 58–9, 280, 281, 318
 bacterium–epithelium interaction 258–9, 260, 261–3, 264
 β_2 -adrenoceptor agonists 392–3, 396
 CF pathophysiology 67
 COPD pathophysiology 62, 63, 64, 65, 66, 288
 dendritic cells 204–5, 262
 epithelial production of 329–35, 341
 glucocorticoids 368, 371–3, 374, 375, 376, 377, 381, 396
 goblet cell metaplasia 6
 IgA production 213
 integrin-mediated activation of TGF- β 42–3
 microbial recognition 175, 177, 228–9, 257, 258–9, 260

- pollutants 278, 279, 280, 281, 282,
 284–6, 288
 surfactant proteins 154
 viral infections 231–6, 237–8, 239–40, 241,
 242, 282
- Defensins 175, 188–9, 193–4, 229–30, 262
 dendritic cells 203
 epithelial production 334, 337
 pollutants 285
 T-cells 208
- Dendritic cells (DC) 201–5, 209
 airway remodelling 352
 allergens 302–3, 305, 310, 314, 318
 epithelial cell regulation of 202–5, 262,
 331, 334
 T-cell activation by 210–1, 331
- Der p proteins 305–6, 307, 308–9, 310–6,
 317–18, 319–20
 asthma 58–9, 63, 353–4
- Desmin 36
- Desmocollins (Dscs) 30, 36
- Desmogleins (Dsgs) 30, 36
- Desmoplakin (DP) 37
- Desmosomal cadherins 30, 35(n3), 36
- Desmosomes 27, 28, 36–7, 77, 82, 314–16
- Diesel exhaust particles (DEP) 63–4, 204, 242,
 283, 284, 285
- DPPC 147–8, 151, 155
- Drug absorption 417–22
- Drug delivery systems 411–17, 422–3
- Dynein arms 3, 112, 113, 114–15,
 116, 118
- E-cadherin 30, 35, 204
- Elafin 190, 194, 204, 342
- Embryonic stem cells 13–14
- Emphysema 64–5, 136
- Endothelins 132, 286, 337
- Envoplakin 37
- Eosinophils
 asthma 59, 61, 85, 357
 epithelial regulation 334–5
 epithelial shedding-repair 85
 viral infections 231–2, 237
- Eotaxins 318, 333–4, 368, 396
- Epidermal growth factor (EGF) 85, 133, 332,
 360, 361
- Epidermal growth factor receptor (EGFR) 264,
 288, 332, 354–5
- Epithelial cadherin, *see* E-cadherin
- Epithelial lining fluid (ELF) 276–7
- Epithelial mesenchymal trophic unit (EMTU)
 361
- Epithelial neutrophil attractant (ENA)-78 231,
 333, 334
- Epithelial sodium channels (ENaC) 90, 91, 92,
 96–7, 104–5, 106, 107, 377–9
- ERK MAP kinases 304
 allergens 319
 COPD 62–3
 glucocorticoids 375, 376
 pollutants 284, 285, 288
 viral infections 233, 240
- Erythropoietin (Epo) 420–1
- Exotoxins 265
- Fetal airway 90, 352, 361, 379
- Filaggrin 321
- Flagella 255, 256, 257, 259–60, 262
- Flagellin 259–60, 261, 263
- Fluid
 airway/alveolar physiology 89–92
 transport 91–3, 94–5, 96, 97–9, 100–7,
 377–9
- Focal adhesions 28, 39
- Fractalkine (CX3CL1) 203, 237–8,
 333, 335
- Fungal allergens 306, 306–8, 310, 314,
 318, 320
- Fusion protein transport 420–1
- Gap junctions 28
- Gas exchange region 2, 11–12, 15
 see also Alveolar epithelial cells
- Gene expression, glucocorticoid-dependent
 368–76, 380, 381, 397–401
- Gene therapy 421
- Genetic linkage analysis, PCD 118
- Genetic variations
 AMPs 193–4
 asthma 359, 361
 TLR 172
- Glucocorticoid-inducible leucine zipper (GILZ)
 375–6, 381, 399, 400
- Glucocorticoid receptor (GR) 368–70, 371–3,
 378, 400–1
- Glucocorticoid response elements (GREs)
 368–70, 372, 397–400
- Glucocorticoids 60, 63, 84, 212, 367–82
 with β_2 -agonists 391, 392, 393–401
- Glutathione (GSH) 343, 354

- Goblet cells 5–6
 asthma 60, 137, 139, 140, 357, 360
 CFTR expression 94
 COPD 139, 140
 hyperplasia 5, 6
 anti-inflammatory process 140–1
 asthma 60, 137, 140, 360
 COPD 135, 140
 cystic fibrosis 137, 140
 glucocorticoids 377
 inducers 132–3
 mechanisms 137
 metaplasia 5–6, 357, 360
 mucin production 93, 130, 131, 133, 134, 139, 140–1
- Granulocyte–macrophage colony stimulating factor (GM-CSF) 331, 332
 allergens 318, 320, 332
 antigen presentation 210
 asthma 355
 β_2 -adrenoceptor agonists 392, 396
 calcium activation of 263
 dendritic cells 204, 204, 205, 262
 glucocorticoids 374
 pollutants 284, 285
- Granulocytes 76, 78, 82, 85
- Growth factors, *see* Cytokines and growth factors
- Growth-related oncogene (GRO)- α (CXCL1) 62, 231, 237, 289, 333, 334
- H5N1 virus 239
- Haemophilus influenzae*
 AMPs 194
 bacterial co-infection 241
 ciliary dysfunction 118
 community-acquired pneumonia 253
 COPD 227, 254, 264
 cystic fibrosis 254
 epithelial cell response to 263
 recognition by epithelium 170, 172, 175, 259
- Health care associated pneumonia 253–4
- Heat shock proteins 203, 354–5, 368, 392
- Hemidesmosomes 28, 44–5
- House dust mites, *see* Mite allergens
- Human (h)CAP-18 189, 192
- Hydrogen peroxide 195–6, 338–9
- Hydroxyeicosatetraenoic acids (HETEs) 335, 336
- Hypothiocyanite 195, 196
- ICE-protease activating factor (IPAF) 260, 261
- I κ B kinase (IKK) complex 173–4, 229, 240, 371
- Immune system
 airway remodelling 352
 allergen–epithelium interaction 301–4, 305–6, 310–6, 320–1
 antimicrobial molecules 175, 187–97, 229–30, 257, 262–3, 337
 β_2 -adrenoceptor agonists 392
 epithelial regulation of 201–14, 257, 261–5, 302–4, 310–6, 320–1, 329–44
 gene therapy 421
 microbial recognition 169–78, 192, 228–9, 256–61
 pollutant–epithelium interactions 279, 285
 surfactant 147, 152–4, 159–60, 190, 229
- Immunizations, inhaled 422–3
- Immunoglobulins (Igs)
 aerosol delivery 423
 allergens 305–6, 318, 320
 fusion protein transport 420
 IgA production 212–14
 junctional adhesion molecules 29, 30, 33–4, 304, 341
- Indoleamine 2,3-dioxygenase (IDO) 196, 209
- Inflammasomes 261
- Inflammatory cells and mediators
 airway mucus secretion 132–3, 138–9
 allergens 317–20
 AMPs 191, 192, 194–5, 262, 337
 asthma pathophysiology 58–60, 67, 85, 280, 281
 airway remodelling 351–3, 357, 359, 360, 361, 376–7
 asthma–COPD comparison 138–9
 athletes 67
 bacterium–epithelium interaction 258–9, 261–4, 265
 β_2 -adrenoceptor agonists 392–3, 396–7
 CF pathophysiology 67
 ciliary dysfunction 119
 COPD pathophysiology 62, 63, 64, 65, 66, 67, 402
 epithelial regulation of 329–44
 epithelial repair 83–4
 glucocorticoids 367–82, 396–7
 microbial recognition 173, 174, 175, 228–9, 257, 258–9
 pollutants 277–8, 279, 280, 281, 284–6, 288, 289

- surfactant proteins 153, 154, 159–60
see also Specific cells and mediators
- Influenza viruses 239–40
 air pollutant interaction 242
 allergic sensitization 241
 antimicrobial molecules 229, 230
 asthma exacerbation 227
 bacterial co-infection 241
 bronchiolitis 226
 community-acquired pneumonia 226
 inhaled immunization 423
 recognition by epithelium 171, 177, 228
- Inhaled drugs 391, 393–401, 412–17, 422–3
- Inner dynein arms (idas) 3, 112, 113, 114, 118
- Insulin, inhaled 422
- Integrins 30, 31, 38–45, 341
- Intercellular adhesion molecule 1 (ICAM-1) 175, 341
 action on T-cells 211
 bacterial–epithelial interactions 262
 dendritic cells 204, 205
 pollutants 282, 289
 RV infection 232, 233, 241, 242, 282
- Interferon-inducible protein (IP)-10/CXCL10 204–5, 209, 231, 238, 333, 334
- Interferons (IFNs) 331–2
 antigen presentation 210, 211
 bacterial infection 263
 COPD pathophysiology 62, 65
 fractalkine 335
 viral infection 236, 239–40, 241, 332
- Interleukin-1 receptor-associated kinase (IRAK) 173, 263
- Interleukin-10 (IL-10) 203, 208, 213, 279, 281, 331
- Interleukin-11 (IL-11) 330, 373, 374
- Interleukin-13 (IL-13)
 airway mucus secretion 132
 AMPs 192
 asthma 58, 233, 234
 goblet cell metaplasia 6
 pollutants 279, 281
- Interleukin-15 (IL-15) 204, 208–9
- Interleukin-16 (IL-16) 208
- Interleukin-18 (IL18) 331
 airway mucus secretion 132
 β_2 -adrenoceptor agonists 392
 COPD pathophysiology 63, 64, 66
 dendritic cells 204
 glucocorticoids 368, 374
 pollutants 279, 286
- Interleukin-2 (IL-2) 213
- Interleukin-4 (IL-4) 58, 192, 204
- Interleukin-5 (IL-5) 213, 279, 281, 357
- Interleukin-6 (IL-6) 330
 action on T-cells 206
 airway mucus secretion 132
 allergens 318, 320
 asthma pathophysiology 58
 COPD pathophysiology 62, 288
 dendritic cells 204
 epithelial cell receptor shedding 264
 glucocorticoids 368, 374
 IgA production 213
 microbial recognition 175
 pollutants 279, 284, 285, 286, 288
- Interleukin-8 (IL-8; CXCL8) 333, 334
 action on T-cells 209
 allergens 318, 319, 320
 AMP function 194
 asthma pathophysiology 58, 59, 61, 64, 282, 318, 355
 bacterium–epithelium interaction 64, 258, 261–2, 263, 264
 β_2 -adrenoceptor agonists 392, 396
 CF pathophysiology 67
 COPD pathophysiology 62, 63, 64, 66
 glucocorticoids 368, 371, 373, 374
 influenza infection 240
 microbial recognition by epithelium 175, 258
 pollutants 62, 63, 64, 278, 279, 282, 284, 285, 289
 RSV infection 237, 238
 RV infection 231, 233–6, 282
- Intermediate filaments (IFs) 28, 36, 37, 44
- Ion transport 89–107
 airway ion absorption 96–7
 alveolar epithelial cells 106–7
 ASL regulation 101–5
 bacterial infection 263
 fluid's physiological role 89–92
 glucocorticoids 377–9, 380
 'leak-pump' mechanism 91, 92–3
 measurements 97–104
 potassium channels 91, 92, 95–6, 377–9
- Ionic environment, AMP activity 193
- Iron 255, 284–5
- Isolated aggregations of lymphoid cells (IALC) 206

- JNK MAP kinases 304
 allergens 319
 bacterial infection 263
 glucocorticoids 375
 influenza infection 240
 pollutants 284, 285, 288
- Junctional adhesion molecules (JAMs) 29, 30, 33–4, 304, 341
- Keratinocyte growth factor (KGF) 361
Klebsiella pneumoniae 176, 254, 259
- Lactoferrin 188, 189, 192, 255
 Lactoperoxidase (LPO) 195–6
 Lamellar bodies (LBs) 155, 156
 Lamina reticularis (LR) 352, 356–7
 Langerhans cells (LC) 203
 Laplace's Law 149, 150
 Large surfactant aggregates (LA) 156–7
 'Leak-pump' mechanism 91, 92–3
Legionella spp 177, 259, 261
 Leukocyte–epithelial interactions 341
 Leukotrienes 335, 336, 376
 Lipid mediators 335–6, 376
 Lipids, ozonation 276–7
see also Phospholipids (PL)
 Lipopolysaccharide (LPS) 170, 259, 262–3, 374
 Lipoxins 335, 336
 Lipoxygenase pathway 335, 336, 376
 LL-37 189, 192, 194, 262, 337
 Lung cancer 36, 37, 44, 286–7, 288–9
 Lung regenerative medicine 13
 Lymphoid immune system 205–6
see also B-cells; T-cells
 Lysozyme 188, 189–90, 192
- M cells 205
 Macrophage inflammatory peptides (MIPs) 204, 209, 237, 285, 334, 335
 Macrophages
 aerosol drug uptake 416–17
 AMPs 192
 COPD pathophysiology 65, 66
 ICE-protease activating factor 261
 reactive oxygen species 195
 surfactant metabolism 156, 157
 surfactant proteins 153, 154
 Major histocompatibility (MHC) molecules 210, 211
 Mannose binding lectin (MBL) 229
 MAPK phosphatase (MKP)-1 374–5, 376, 381
 Matrix metalloproteinases (MMPs) 83, 340–1, 342
 Matrix proteins 358, 359
 Melanoma differentiation-associated gene 5 (Mda-5) 177, 228
 Metal particles 284–5, 287
 Metapneumovirus 226
 Methicillin-resistant *S. aureus* (MRSA) 254
 Microbial recognition 169–78, 192, 228–9, 256–61
 Microvasculature 359–60
 Mite allergens 305–6, 307, 308–16, 317–18, 319–20
 asthma 58–9, 63, 353–4
 cigarette smoke 63
 Mitogen-activated protein (MAP) kinases
 allergens 304, 319, 320
 bacterial infection 263, 264
 COPD pathophysiology 62–3, 64
 glucocorticoids 374–5, 376, 381
 microbial recognition 173
 pollutants 284, 285, 288
 viral infections 232, 233, 240
 Monocyte chemoattractant protein (MCP)-1/CCL2 209, 237, 262, 264, 334, 335, 368
Moraxella catarrhalis 227, 253, 254
 MUC genes and gene products 130, 131–2, 133–4, 138
 asthma 134, 139, 360
 bacterium–epithelium interactions 262–3
 pollutants 288
 Mucins 93, 129, 130–4, 138, 139
 asthma 134, 139, 360
 biofilm production 256
see also MUC genes and gene products
 Mucociliary apparatus
 dysfunction 118–20, 135–6, 140
 function 3–4, 111, 114–18
 pollutants 277
 structure 3, 111–14
see also Mucus
 Mucous gland cells 2, 3, 9, 130, 140
 Mucus 127–41
 activity of AMPs in 192, 193
 aerosol absorption 415, 416
 composition 93, 127–9, 130–4
 functions 127, 128
 gene therapy 421
 hypersecretion 127, 129, 134–6, 137–41, 360

- ion transport 89, 90, 91, 93, 101–2, 104, 105
mucociliary clearance 136–7, 140, 193, 415
see also Airway surface liquid (ASL);
Mucins; Mucociliary apparatus
- Muscarinic receptor antagonists 391–2, 401–4, 414
- Mycobacterium* spp 119, 170, 176
- Myeloid differentiation (MyD)-88 173, 174, 228, 258–9, 260, 263
- NADPH oxidase 195, 196
- NALPs (NACHT-, LRR- and pyrin-domain-containing proteins) 260, 261
- Necrosis, epithelial cells 59, 61, 64–5
- Neonatal respiratory distress syndrome (NRDS) 149, 157, 158, 379
- Nerve growth factors (NGFs) 238, 360
- Neural pathways 133, 360
- Neuraminidases, bacterial 255, 256
- Neuroendocrine bodies (NEBs) 7
- Neurogenic airway inflammation 238
- Neurokinins 133, 238, 278
- Neutrophils
AMPs 189, 190, 194
asthma pathophysiology 59–60, 61, 85
bacterium–epithelium interaction 261–2, 263
CF pathophysiology 67
ciliary dysfunction 119, 120
COPD pathophysiology 62, 64, 66
epithelial regulation 334, 336, 341, 342
epithelial repair 81, 85
protease inhibition 420
reactive oxygen species 195
viral infections 231, 236, 237
- Nexins 113
- NF- κ B
allergens 319
bacterial infection 228, 261, 262, 263, 264
COPD pathophysiology 63, 64
glucocorticoids 371–3, 375–6, 397
influenza infection 240
microbial recognition 173, 174, 228
pollutants 278, 284–5, 289
- Nitric oxide
action on T-cells 207–8, 230
airway mucus secretion 132
antimicrobial activity 196, 230, 263, 339–40
dendritic cells 203
epithelial production 338, 339–40, 343
pollutants 284
- Nitric oxide synthase (NOS) 230, 263, 284
- Nitrogen dioxide 64, 242, 276, 277–9, 281–2
- Nitrosamines, tobacco-specific 289
- Nod-like receptors (NLRs) 176–7, 260–1, 263
- Nosocomial pneumonia 253–4
- Novel therapies 411–23
- Nuclear factor- κ B, *see* NF- κ B
- Nucleotide binding domains (NBDs) 94
- Nucleotide–nucleoside system 105
- Occludin 29–31, 30, 303–4, 311, 312–13
- Occupational allergy 307–8
- Osmosis 91–3, 91
- Outer dynein arms (odas) 3, 112, 113, 114, 116, 118
- Oxidant pollutants 64, 67, 242, 276–82
- Oxidative stress 62, 63, 64–6, 339, 354
- Ozone 64, 67, 242, 276–82
- p38 MAP kinases 304
allergens 319
bacterial infection 263
COPD pathophysiology 63
glucocorticoids 374–5, 376
influenza infection 240
pollutants 284, 285
- P57^{kip2} 399–400
- Parabasal cells 4–5
- Paracellin-1 (claudin-16) 33
- Parainfluenza viruses 226, 227, 230
- Particulate matter (PM) 282–7
diesel exhaust 63–4, 204, 242, 283, 284, 285
- Partitioning-defective protein (PAR)-3 34
- Pattern recognition receptors (PRRs) 169–78, 228–9
AMPs 191, 192, 262
host-derived agonists 177–8
intracellular 176–7, 178, 260–1, 263
non-TLR 175–6
toll-like, *see* Toll-like receptors (TLRs)
transmembrane 169, 178
see also RNA helicases (RHs)
- Peptidase allergens 305–20, 321
- Peptidase degradation 420
- Peptidase receptors 304
see also Protease-activated receptors (PARs)

- Peptide mediators, epithelial production
337, 343
see also Antimicrobial peptides and proteins (AMPs); Endothelins
- Peptidoglycan recognition proteins (PGLYRPs)
191, 257
- Periciliary fluid (PCF) 102, 120
- Periciliary liquid layer 111, 129
- Periplakin 37
- PH dependent CBF modulation 117–18, 119, 120
- Phospholipids (PL)
ozonation 276–7
surfactant 147–8, 422
biophysical function 151, 152
immune function 153
synthesis 155, 156, 157
- PhoX* 195, 196
- Pili 254, 257
- Plakins 37
- Plakoglobin (PG) 37
- Plakophilins (PPs) 37
- Plasma-derived gel 75–6, 78, 81, 82, 84
- Plasma proteins, epithelial repair 76, 81, 85
- Platelet activating factor (PAF) 133, 336, 376
- Plectin 37, 44–5
- PLUNC proteins 190–1
- Pneumonia 226, 253–4, 256, 261–2, 264
- Polarity, epithelial cell 41–2
- Pollutants 275–91
asthma 61, 242, 278, 280–2, 285
COPD 62–6, 67, 285, 288, 343
dendritic cells 204
viral infection interactions 242, 281–2
see also Cigarette smoke
- Potassium channels 91, 92, 95–6, 377–9
- Potential differences (PDs) 91, 92, 98, 99–100, 102
- Primary ciliary dyskinesia (PCD) 118
- Prostaglandins
action on T-cells 206–7
airway mucus secretion 133
dendritic cells 203
epithelial production 336, 376
glucocorticoids 374, 376
pollutants 276, 279, 285, 289
- Protease-activated receptors (PARs) 58, 304, 317–20, 355
- Protease degradation 420
- Proteases
epithelial production 340–5
production of inhibitors of 342
- Protein clearance 420
- Protein kinases 235, 278
see also Mitogen-activated protein (MAP) kinases
- Protein transport 418–19, 420–1
- Pseudomonas aeruginosa*
AMPs 194
CBF effects 119
cystic fibrosis 254, 256
epithelial cell responses 261, 262, 263, 264
nosocomial pneumonia 254
recognition by epithelium 171, 172, 173, 176, 258–9, 260
type III secretion system 264–5
virulence factors 254, 255, 256
- Pulmonary neuroendocrine cells (PNECs)
2, 3, 7
- Pyochelin system 255
- Pyoverdinin system 255
- Quorum sensors 255
- RANTES (CCL5) 174–5, 204–5, 209
allergens 318, 334–5
asthma 355
 β_2 -adrenoceptor agonists 392
epithelial regulation 334–5
glucocorticoids 368
viral infections 229, 231–2, 237, 238, 239, 240
- Reactive nitrogen species
action on T-cells 207–8, 230
airway mucus secretion 132
antimicrobial function 195, 196, 230, 263, 339–40
dendritic cells 203
epithelial production 337, 338, 339–40, 343
pollutants 277, 284
- Reactive oxygen species
airway mucus secretion 132
antimicrobial function 195–6
asthma 354, 360
ciliary dysfunction 119
epithelial production 337–9, 343
pollutants 284, 288
- Remodelling 85–6, 351–61, 376–7, 393
- Repair of pulmonary epithelium
after shedding 75–86

- airway remodelling 85–6, 353–5
- AMPs in 194
- growth factors 332
- role of integrins 40, 43
- Respiratory syncytial virus (RSV) 236–8
 - air pollutant interaction 242
 - allergic sensitization 241
 - asthma exacerbation 60, 227, 236–7, 377
 - bacterial co-infection 241
 - bronchiolitis 226, 236, 237
 - combination therapies 396
 - community-acquired pneumonia 226
 - epithelial cell apoptosis 240
 - innate host defence 170, 171, 228, 229, 237–8
 - lower respiratory tract infection 227
 - neurogenic airway inflammation 238
 - T-cell activation 211–12
- Respiratory viruses and infections 225–42
 - air pollutant interactions 242, 281–2
 - allergic sensitization 241
 - asthma exacerbation 60, 211, 225, 226–7, 231–7, 242, 281–2, 332, 377
 - bacterial co-infection 241, 242
 - bronchiolitis 226, 236, 237
 - ciliary dysfunction 119
 - combination therapies 396
 - community-acquired pneumonia 226
 - COPD exacerbation 225, 226, 227, 231, 234, 241
 - epithelial repair 83
 - gene therapy 421
 - innate host defence 228–30
 - antimicrobial molecules 187–8, 196
 - recognition by epithelium 170, 171, 172, 176, 177, 228–9
 - surfactant proteins 153–4
 - lower respiratory tract 227
 - T-cell activation 211–12
 - vaccines 212
- Retinoic-acid-inducible protein I (RIG-I) 177, 228, 238, 240
- Rhinitis 84–5, 301
- Rhinoviruses (RVs) and infections 231–6
 - air pollutants 242, 282
 - asthma exacerbation 226, 227, 231–6, 242, 282, 332, 377
 - bacterial co-infection 241
 - bronchiolitis 226
 - combination therapies 396
 - community-acquired pneumonia 226
 - COPD exacerbation 226, 227, 231, 241
 - epithelial repair 83
 - innate host defence 171, 228, 229–30
 - interferons 236, 332
 - lower respiratory tract 227–8
 - T-cell activation 211
- Rho GTPase Rac1 232–3, 233
- RNA helicases (RHs) 176, 177, 228, 238, 240
- Salt-dependent AMP activity 193
- SARS-coronavirus 176, 230
- Secretory cells 3, 5–6, 81–2
- Secretory component (SC) 214
- Secretory leukocyte protease inhibitor (SLPI) 190, 192, 194
 - cystic fibrosis 342, 420
 - dendritic cells 203
 - glucocorticoids 370, 381
- Serous cells 2, 3, 6, 8–9
 - asthma 140
 - cell–cell adhesion 29
 - CFTR expression 8–9, 94
 - COPD 140
 - goblet cell hyperplasia 137, 141
 - mucin production 130
- Serpins 317
- Serum and glucocorticoid-inducible kinase (SGK)-1 379
- Shear stress, airway 104–5
- Shedding 57–8, 61, 67, 75–86, 134
- Siderophores 255
- Small surfactant aggregates (SA) 156–7
- Smooth muscle 58, 352, 358–9, 393, 413–14
- Sodium channels 90, 91, 92, 96–7
 - alveolar epithelium 106, 107
 - ASL volume regulation 102–5
 - glucocorticoids 377–9, 380
 - Ussing chamber studies 98, 99
 - in vivo transepithelial PDs 100
 - volume flow measurements 100–1
- Solute transport 91–3, 94–5, 96, 97–9, 100–7, 377–9
- SPLUNC proteins 190–1
- Staphylococcus aureus*
 - antimicrobial molecules 196
 - cystic fibrosis 254
 - epithelial cell responses 263, 264
 - pneumonia 253, 254, 260
 - recognition by epithelium 172, 175, 176, 258, 260

- Staphylococcus aureus* (Continued)
 viral co-infection 241
 virulence factors 254, 255
- Stem cell niches 4, 7, 9, 10, 12, 14, 15
- Stem cell therapy 13–14
- Stem cells, circulating 13
- Streptococcus pneumoniae*
 community-acquired pneumonia 226, 253
 COPD 227, 254
 epithelial cell response 263
 recognition by epithelium 170–1, 175, 258, 260–1
 viral co-infection 241
 virulence factors 254, 255, 256
- Streptococcus pyogenes* 176
- Submucosal glands (SMGs) 2, 2, 3
 airway surface liquid 90
 asthma 140
 cell types and functions 8–9, 93
 CFTR expression 94
 COPD 135, 140
 mucin production 130, 133, 134, 140
 reactive oxygen species 195
- Substance P 133, 238, 278
- Sulfur dioxide 242
- Superoxide radicals 343, 354
- Surface tension 149–52
- Surfactant proteins (SP) 147, 148–9
 biophysical function 151–2
 glucocorticoids 379
 immune function 153–4, 159–60, 190, 229, 241
 synthesis 155–6
- Surfactant system 147–60
 ARDS 157, 158–60
 biophysical function 147, 149–51
 exogenous surfactant therapy 158, 159–60, 422
 immune function 147, 152–4, 159–60, 190, 229
 normal metabolism 12, 154–7
 NRDS 149, 157, 158, 379
 surfactant composition 11–12, 147–9
- T-cell zone, BALT 205
- T-cells
 action of NO on 207–8, 230
 allergens 305–6, 318
 asthma pathophysiology 58, 59, 61, 231–2, 351, 352
 COPD pathophysiology 65, 66
 epithelial regulation of 206–9, 210–2, 331
 gamma/delta type 212
 isolated aggregations of lymphoid cells 206
 obliterative bronchiolitis 67
 pollutants 279
 regulation by epithelial cells 206, 207, 208, 335
 viral infections 231–2, 237
- TACE (TNF- α converting enzyme) 264, 360
- TANK-binding kinase (TBK)-1 174, 228–9
- Thiocyanate 196
- Thymic stromal lymphopoietin (TSLP) 203, 207, 330, 331
- Thymus and activation regulated chemokine (TARC; CCL17) 59, 335
- Tidal breathing, shear stress 104–5
- Tight junctions (TJs) 27, 28, 29–34, 30
 allergens 303–4, 310–7, 320–1
 asthma 353–4
 dendritic cells 203
 drug absorption 417–18
 epithelial shedding-repair 79, 82, 314–16
- Tissue inhibitor of metalloproteinases (TIMP) 340, 342
- Toll-like receptors (TLRs) 169–75, 177–8, 192, 228
 bacterial infections 170–2, 258–60, 262, 263
 COPD 241, 242
 viral recognition 170, 171, 172
 influenza 240
 RSV infection 238
 RV infection 234–5, 241
- Tracheal epithelium 2–8, 29, 172–3
- TRAM 173, 174, 263
- Transcriptional repression 368–76, 380, 381, 397–401
- Transcytosis 418–19
- Transforming growth factor (TGF)- β
 331, 332
 action on T-cells 208
 airway remodelling 356, 357, 360, 377
 COPD pathophysiology 62, 63
 dendritic cells 203
 glucocorticoids 374, 377
 IgA production 213
 Integrin-mediated activation 42–3
- TRIF 173, 174, 228, 263
- Tristetraprolin (TTP) 374, 381

- Tuberculosis (TB) 172
- Tubular myelin (TM) 155–6
- Tumour necrosis factor (TNF)- α
- airway mucus secretion 132
 - asthma pathophysiology 59
 - bacterium–epithelium interaction 258, 260, 261, 262, 264
 - β_2 -adrenoceptor agonists 392, 396
 - COPD pathophysiology 62, 65, 66
 - dendritic cells 204
 - glucocorticoids 368, 374, 375, 379
 - influenza infection 239–40
 - microbial recognition 175, 258, 260
 - pollutants 278, 279, 284, 285
- Tumour necrosis factor (TNF)- α converting enzyme (TACE) 264, 360
- Tumour necrosis factor receptor-associated factor 6 (TRAF6) 173, 228–9, 263
- UCHL1 288–9
- Ussing chamber studies 97–9
- Vaccines, aerosolized 422–3
- Vascular endothelial growth factor (VEGF) 204, 331, 332, 360, 377
- Vascular remodelling 359–60
- Ventilator-associated pneumonia 254
- Vimentin 36
- Viruses, *see* Respiratory viruses and infections
- Viscoelasticity, mucus 129
- Vitamin D 192
- Volume regulation, ASL 101–5
- Volume transport 100–1
- Water surface tension 149–52
- Water transport 91–3, 96, 97–9, 100–7, 377–9

